Reliable Active Pharmaceutical Ingredient Manufacturer Supporting Global Healthcare

Ticagrelor is the first reversibly binding oral P2Y₁₂ platelet receptor antagonist, featuring a complex cyclopentane-triazolopyrimidine structure with multiple stereocentres. Structurally, Ticagrelor consists of a triazolo[4,5-d]pyrimidine core with a propylthio substituent at the 5-position, a cyclopropylamino group at the 7-position, and a cyclopentane ring bearing three hydroxyl groups and a hydroxyethoxy substituent.

Regorafenib Monohydrate is an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases. Structurally, Regorafenib Monohydrate consists of a 4-phenoxy-N-methylpicolinamide core with a urea linkage connecting to a 4-chloro-3-(trifluoromethyl)phenyl group, and a fluorine substituent on the central phenyl ring.

Raltitrexed is a potent and specific thymidylate synthase (TS) inhibitor, belonging to the quinazoline folate analogue class of antineoplastic agents. Structurally, Raltitrexed consists of a 2-methyl-4-oxo-quinazoline ring system linked via a methyl-methylamino bridge to a thiophene ring, which is further connected to a glutamic acid moiety through a carboxamide linkage.

Aprepitant is a selective high-affinity antagonist of the human substance P/neurokinin 1 (NK₁) receptor, featuring a complex morpholine core with three stereocenters that define its pharmacological activity. The molecule consists of a 1,2,4-triazol-3-one ring linked via a methylene bridge to a 2,3-disubstituted morpholine ring, which carries a 4-fluorophenyl group and a chiral 1-[3,5-bis(trifluoromethyl)phenyl]ethoxy substituent.

Enzalutamide (CAS 915087-33-1) is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potent antineoplastic activity. Chemically, Enzalutamide is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, featuring a non-aromatic five-membered ring core with a thioxoimidazolidinone scaffold substituted with cyano-trifluoromethylphenyl and fluoro-N-methylbenzamide groups.

Tafamidis Meglumine (CAS 951395-08-7) is the meglumine salt form of tafamidis, a small molecule pharmacological chaperone targeting transthyretin (TTR). Chemically, Tafamidis Meglumine is a 1:1 salt composed of the active benzoxazole carboxylate anion (2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate) and the meglumine cation (1-deoxy-1-(methylamino)-D-glucitol) .